Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA II: Industry Shares Stage With FDA

Executive Summary

Public meeting departs from usual format, allowing industry representatives to sit next to FDA and answer audience questions as generic during user fee agreement outlined.

Advertisement

Related Content

Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I
ANDA Holder Fee Will Start With Industry-Driven Database 'Clean-Up'
Biosimilar Guidance Development Timelines Criticized By Docs And Patients
Generic Drug User Fees Will Jump More Than 50% In FY 2018

Topics

Advertisement
UsernamePublicRestriction

Register

PS119376

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel